Your browser doesn't support javascript.
loading
SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)
Cassinello, J; Arranz, JA; Piulats, JM; Sánchez, A; Pérez-Valderrama, B; Mellado, B; Climent, MA; Olmos, D; Carles, J; Lázaro, M.
Afiliación
  • Cassinello, J; Hospital Universitario de Guadalajara. Medical Oncology Department. Guadalajara. Spain
  • Arranz, JA; Hospital Universitario Gregorio Marañón. Medical Oncology Department. Madrid. Spain
  • Piulats, JM; Institut Català d’Oncologia. Medical Oncology Department. Barcelona. Spain
  • Sánchez, A; Consorcio Hospitalario Provincial de Castellón. Medical Oncology Department. Castellón de la Plana. Spain
  • Pérez-Valderrama, B; Hospital Universitario Virgen del Rocío. Medical Oncology Department. Sevilla. Spain
  • Mellado, B; Hospital Clinic. Medical Oncology Department. Barcelona. Spain
  • Climent, MA; Fundacion Instituto Valenciano de Oncología. Medical Oncology Department. Valencia. Spain
  • Olmos, D; Hospital Universitario Virgen de la Victoria. Medical Oncology Department. Málaga. Spain
  • Carles, J; Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology. Barcelona. Spain
  • Lázaro, M; Hospital Universitario de Vigo. Medical Oncology Department. Vigo. Spain
Clin. transl. oncol. (Print) ; 20(1): 57-68, ene. 2018. tab
Article en En | IBECS | ID: ibc-170468
Biblioteca responsable: ES1.1
Ubicación: BNCS
ABSTRACT
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma (AU)
RESUMEN
No disponible
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Neoplasias de la Próstata / Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos / Antineoplásicos Tipo de estudio: Guideline Límite: Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Neoplasias de la Próstata / Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos / Antineoplásicos Tipo de estudio: Guideline Límite: Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2018 Tipo del documento: Article